Combining antiangiogenics to overcome resistance: Rationale and clinical experience

Clinical Cancer Research

Volumn 18, Issue 14, 2012, Pages 3743-3749

  Garcia, Victor Moreno ^a   Basu, Bristi ^a   Molife, L Rhoda ^a   Kaye, Stan B ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; AXITINIB; BAY 579352; BEVACIZUMAB; BRIVANIB; CA 4P; CEDIRANIB; COMBRETASTATIN A4 PHOSPHATE; CROLIBULIN; DENIBULIN; DOVITINIB; LEXIBULIN; MOTESANIB; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NINTEDANIB; OMBRABULIN; ORANTINIB; PAZOPANIB; PLINABULIN; RAMUCIRUMAB; SEMAXANIB; SORAFENIB; SUNITINIB; TELATINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VADIMEZAN; VANDETANIB; VATALANIB; VERUBULIN; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; NICOTINAMIDE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ASTHENIA; BLEEDING; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TARGETING; DRUG TOLERABILITY; ENDOTHELIUM CELL; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GLIOBLASTOMA; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HOARSENESS; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOPHOSPHATEMIA; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; NAUSEA; NEUROPATHIC PAIN; NEUTROPENIA; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN TARGETING; PROTEINURIA; QT PROLONGATION; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; METABOLISM; NEOPLASM;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863888220     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1275     Document Type: Review

References (76)

1. Youngner JS, Algire GH. The effect of vascular occlusion on transplanted tumors. J Natl Cancer Inst 1949;10:565-79.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
3. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-6. (Pubitemid 43093958)
4. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991;13:31-6. (Pubitemid 21892580)
5. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34. (Pubitemid 46089673)
6. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42. (Pubitemid 38702844)
7. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
8. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24. (Pubitemid 46089672)
9. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. (Pubitemid 44917502)
10. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34. (Pubitemid 36910021)
11. Burger RA, Brady MF, Bookman MA, Walker JL, Homesley HD, Fowler J, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J Clin Oncol 28;18s, 2010 (suppl; abstr LBA1).
12. Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat 2010;122:1-7.
13. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422-8.
14. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
15. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011;29:11-6.
16. Rini BI, Escudier B, Tomczak P, Kaprin A, Hutson TE, Szczylik C, et al. Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial. J Clin Oncol 29;7s, 2011 (suppl; abstr 4503).
17. Shepard DR, Rini BI, Garcia JA, Hutson TE, Elson P, Gilligan T, et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol 26:15s, 2008 (suppl; abstr 5123).
18. Paglino C, Porta C. Sequencing or not sequencing multikinase inhibitors in kidney cancer: this is the dilemma. Oncol Rev 2010;4:1-3.
19. Goh PP, Sze DM, Roufogalis BD. Molecular and cellular regulators of cancer angiogenesis. Curr Cancer Drug Targets 2007;7:743-58.
20. Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 2010;21:21-6.
21. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010;468:824-8.
22. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
23. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010;10:505-14.
24. Tozer GM, Kanthou C, Lewis G, Prise VE, Vojnovic B, Hill SA. Tumour vascular disrupting agents: combating treatment resistance. Br J Radiol 2008;81[Spec No 1]:S12-20.
25. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008;14:263-73.
26. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006;313:1785-7. (Pubitemid 44454154)
27. Siemann DW, Shi W. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys 2004;60:1233-40. (Pubitemid 39440810)
28. Siemann DW, Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res 2008;28[4B]:2027-31.
29. Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, et al. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res 2008;14:2210-9. (Pubitemid 351551134)
30. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18:338-40.
31. Sennino B, Kuhnert F, Tabruyn SP, Mancuso MR, Hu-Lowe DD, Kuo CJ, et al. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors. Cancer Res 2009;69:4527-36.
32. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95. (Pubitemid 36554699)
33. Allen E, Walters IB, Hanahan D. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res 2011;17:5299-310.
34. Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, et al. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res 2007;13:4209-17. (Pubitemid 47105985)
35. Hellstr̈om M, Phng LK, Gerhardt H. VEGF and Notch signaling: the yin and yang of angiogenic sprouting. Cell Adhes Migr 2007;1:133-6.
36. Hellstr̈om M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007;445:776-80.
37. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006;444:1083-7. (Pubitemid 46018529)
38. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004;279:12876-82.
39. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005;435: 959-63.
40. Yan M, Callahan CA, Beyer JC, Allamneni KP, Zhang G, Ridgway JB, et al. Chronic DLL4 blockade induces vascular neoplasms. Nature 2010;463:E6-7.
41. Nichol D, Shawber C, Fitch MJ, Bambino K, Sharma A, Kitajewski J, et al. Impaired angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7. Blood 2010;116:6133-43.
42. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009;10:165-77.
43. Fukuhara S, Sako K, Noda K, Zhang J, Minami M, Mochizuki N. Angiopoietin-1/Tie2 receptor signaling in vascular quiescence and angiogenesis. Histol Histopathol 2010;25:387-96.
44. Bartsch G Jr, Eggert K, Soker S, Bokemeyer C, Hautmann R, Schuch G. Combined antiangiogenic therapy is superior to single inhibitors in a model of renal cell carcinoma. J Urol 2008;179:326-32. (Pubitemid 350216716)
45. Hashizume H, Falcón BL, Kuroda T, Baluk P, Coxon A, Yu D, et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010;70:2213-23.
46. Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, Wen S, et al. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 2010;9:145-56.
47. Bozec A, Gros FX, Penault-Llorca F, Formento P, Cayre A, Dental C, et al. Vertical VEGF targeting: a combination of ligand blockade with receptor tyrosine kinase inhibition. Eur J Cancer 2008;44:1922-30.
48. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92:735-45. (Pubitemid 28155313)
49. Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N, et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007;11:53-67. (Pubitemid 46054517)
50. Tvorogov D, Anisimov A, Zheng W, Lepp̈anen VM, Tammela T, Laurinavicius S, et al. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell 2010;18:630-40.
51. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96:1788-95. (Pubitemid 46912024)
52. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009;6:465-77.
53. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, et al.ECOG 2100. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-8.
54. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009;6:327-38.
55. Nathan PD, Judson I, Padhani A, Harris A, Carden CP, Smythe J, et al.A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. JClin Oncol 26:15s, 2008(suppl; abstr 3550).
56. Koh DM, Blackledge M, Collins DJ, Padhani AR, Wallace T, Wilton B, et al. Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol 2009;19:2728-38.
57. Garon EB, Kabbinavar FF, Neidhart JA, Neidhart JD, Gabrail NY, Oliveira MR, et al. A randomized phase II trial of a vascular disrupting agent (VDA) fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage 3B/4 nonsquamous nonsmall cell lung cancer (NSCLC): analysis of safety and activity of the FALCON trial. J Clin Oncol 29;15s, 2011 (suppl; abstr 7559).
58. Gutierrez M, Murgo AJ, Allen D, Turkbey I, Gardner ER, Trepel J, et al. Phase I study of vandetanib (V) and bevacizumab (B) combination therapy evaluating the VEGF and EGF signal transduction pathways in adults with solid tumors and NHL. J Clin Oncol 27:15s, 2009 (suppl; abstr 3522).
59. Duffy AG, Turkbey B, Murgo AJ, Choyke PL, Kim YS, Trepel J, et al. Effect of double VEGF blockade with vandetanib (V) and bevacizumab (B) on tumor permeability in gastrointestinal (GI) cancer patients. ASCO 2010 Gastrointestinal Cancer Symposium (abstr 184).
60. Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, et al. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res 2009;15:6277-83.
61. Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1432-9.
62. Barron H. Important drug warning subject: microangiopathic hemolytic anemia (MAHA) in patients treated with Avastin (bevacizumab) and sunitinib malate. July 2008 [cited 2011 Oct]. Available from: http://www.fda.gov/ downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ ucm126434.pdf
63. Falchook GS, Wheler JJ, Naing A, Hong DS, Moulder SL, Piha-Paul SA, et al. A phase I study of bevacizumab in combination with sunitinib, sorafenib, and erlotinib plus cetuximab, and trastuzumab plus lapatinib. J Clin Oncol 28;15s, 2010 (suppl; abstr 2512).
64. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008;26:3709-14.
65. Lee JM, Sarosy GA, Annunziata CM, Azad N, Minasian L, Kotz H, et al. Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. Br J Cancer 2010;102:495-9.
66. Galanis E, Jaeckle KA, Anderson S, Kaufmann TJ, Uhm JH, Giannini C, et al. NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM. J Clin Oncol 28;15s, 2010 (suppl; abstr 2018).
67. Castellano DE, Capdevila J, Salazar R, Sastre J, Alonso V, Llanos M, et al. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: a phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801). J Clin Oncol 29;15s, 2011 (suppl; abstr 4113).
68. Mahalingam D, Beeram M, Rodon J, Sankhala KK, Mita AC, Benjamin D, et al. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab (B) in combination with sorafenib (S) in patients (pts) with advanced malignant melanoma. J Clin Oncol 28;15s, 2010 (suppl; abstr e19008).
69. Grothey A, Lafky JM, Morlan BW, Stella PJ, Dakhil SR, Steen PD, et al. Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): results of the phase II North Central Cancer Treatment Group study N054C. J Clin Oncol 28;15s, 2010 (suppl; abstr 3549).
70. Schultheis B, Neumann H, Roy R, Kummer G, Strumberg D. Phase I study of paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors. J Clin Oncol (Meeting Abstracts). 2010 May 20, 2010;28(15-suppl):e13079.
71. Chiorean EG, Matei D, Younger A, Funke JM, Waddell MJ, Jones DR, et al. Phase I study of sorafenib (S) with bevacizumab (B) and paclitaxel (P) in patients (pts) with refractory solid tumors. J Clin Oncol 28;15s, 2010 (suppl; abstr 3043).
72. Sharma S, Abhyankar V, Burgess RE, Infante J, Trowbridge RC, Tarazi J, et al. A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann Oncol 2010;21:297-304.
73. Fernando NT, Koch M, Rothrock C, Gollogly LK, D'Amore PA, Ryeom S, et al. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res 2008;14:1529-39. (Pubitemid 351413938)
74. Uronis HE, Bendell J, Blobe G, Morse M, Geier D, Nixon A, et al. A phase I study of bevacizumab (BV) plus ABT-510 in patients with advanced solid tumors. J Clin Oncol 25;18s, 2007 (suppl; abstr 3541).
75. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009;27:3557-65.
76. Rini BI, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, et al. AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): a randomized, double-blind, placebo-controlled, phase II study. J Clin Oncol 29;7s, 2011 (suppl; abstr 309).